Bicycle Therapeutics plc vs Biodexa Pharmaceuticals plc — Valuation Comparison 2026
Access all valuation models for BCYC vs BDRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →BCYC scores higher with a 6.1/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Bicycle Therapeutics plc (BCYC) and Biodexa Pharmaceuticals plc (BDRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
BCYC currently trades at $4.67 with a QOC of 6.1/10, while BDRX trades at $3.36 with a QOC of 1.7/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).